KOSDAQBiotech & Pharma203400

Abion

₩3,380 0.00%2026-11-18 close
Market Cap
₩60.9B
Turnover
₩0
Volume
0 shares
Shares out.
18M
PER
—
PBR
1.3×
EPS
-₩1,593
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Oncology data weighed against cumulative losses

ABN401 Phase 2 data and partnering talks are the key variables, while losses have run for four straight years through 2025 and for five straight quarters from Q3 2025 through Q3 2026.

  1. 1

    ABN401 reported a 55% objective response rate by BICR in a global Phase 2 trial in MET exon 14 skipping NSCLC, presented at ASCO on June 1, 2026.

  2. 2

    The 2025 operating loss narrowed to KRW 19.4 billion from KRW 34.1 billion in 2024, but the four-year run of losses from 2022 through 2025 continued.

  3. 3

    Q3 2026 sales of KRW 320 million rose 97.6% year on year, while the operating loss of KRW 5.27 billion widened from a year earlier.

  4. 4

    A disclosure dated August 14, 2026 lists a trading suspension tied to a listing-qualification substantive review, making the listing process a key variable.

  5. 5

    The debt-to-equity ratio fell from 347.7% in 2023 to 17.9% in 2025, with total equity of KRW 68.4 billion at end-2025, while operating cash outflow grew each year to -KRW 33 billion in 2025.

02

Business structure

Abion is a KOSDAQ-listed innovative drug developer that researches precision-medicine biopharmaceuticals, including targeted and immuno-oncology therapies. The center of its pipeline is ABN401 (babamekip), a highly selective tyrosine kinase inhibitor aimed at the c-MET receptor.

ABN401 is in a global Phase 2 trial in patients with MET exon 14 skipping non-small cell lung cancer, and it holds orphan drug designation at the development stage from Korea's Ministry of Food and Drug Safety.

The second pillar is the iRAC platform, an interferon beta antibody conjugate for next-generation immuno-oncology, for which the company reported securing a U.S. patent in August 2026. Candidates built on iRAC and on CLDN3, including ABN202 and ABN501, are being expanded with the aim of global co-development.

According to the company, unlike conventional antibody-drug conjugates that release a cytotoxic payload inside cells, iRAC is designed to act in the tumor microenvironment. Revenue is small for a company at this stage, so the business model leans on development progress and technology transfer talks.

Listed peers in the same biopharma sector include Alteogen, Hanmi Pharm, Yuhan, and LigaChem Biosciences, although differences in pipeline stage and indications limit direct comparison.

The MET-targeted field where ABN401 competes already has approved drugs, and the company emphasizes efficacy and safety comparable to those.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩200M-₩4.4B−2711.3%
2025Q4₩66,429,524-₩5.6B−8472.1%
2026Q1₩600M-₩6.5B−1139.7%
2026Q2₩100M-₩4.3B−3155.4%
2026Q3₩300M-₩5.3B−1644.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.5B-₩25.2B-₩19.9B−1004.1%−132.0%59.9%
2023₩1.3B-₩31.3B-₩29.2B−2452.5%−292.7%347.7%
2024₩800M-₩34.1B-₩43.4B−4484.2%−154.2%126.7%
2025₩900M-₩19.4B-₩29.1B−2201.0%−42.5%17.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On the disclosed annual figures, sales were KRW 2.51 billion in 2022, KRW 1.27 billion in 2023 (down 49.2% year on year), and KRW 760 million in 2024 (down 40.4%), before rising to KRW 880 million in 2025 (up 15.9%). 2022 was the largest year and 2024 the smallest in the period.

The operating loss was KRW 25.2 billion in 2022, KRW 31.3 billion in 2023, and KRW 34.1 billion in 2024, each year recorded as continued losses with widening deficits, before narrowing to KRW 19.4 billion in 2025 as continued losses with a smaller deficit.

Losses were recorded for four consecutive years from 2022 through 2025. The operating margin deteriorated from -1,004.1% in 2022 to -4,484.2% in 2024 before improving to -2,201.0% in 2025.

Net loss attributable to controlling shareholders was KRW 19.9 billion in 2022, KRW 29.2 billion in 2023, KRW 43.4 billion in 2024, and KRW 29.1 billion in 2025, while net income including non-controlling interests was reported as the same net losses for each year.

In 2024 and 2025, the loss attributable to controlling shareholders was larger than the operating loss, and the non-operating items behind that gap cannot be identified from the disclosed table alone, so they are a point to check in the annual report notes.

Operating cash flow was -KRW 19.9 billion in 2022, -KRW 26.9 billion in 2023, -KRW 28.1 billion in 2024, and -KRW 33 billion in 2025, with the outflow larger each year. The debt-to-equity ratio fell from 347.7% in 2023 to 17.9% in 2025, when total liabilities were KRW 12.2 billion and total equity was KRW 68.4 billion.

Quarterly sales were KRW 162 million in Q3 2025, KRW 66.43 million in Q4 2025 (down 59.0% from the prior quarter), KRW 574 million in Q1 2026 (up 764.4%), KRW 137 million in Q2 2026 (down 76.1%), and KRW 320 million in Q3 2026 (up 133.8% quarter on quarter and up 97.6% year on year), a volatile path.

Quarterly operating losses were KRW 4.39 billion, KRW 5.63 billion, KRW 6.54 billion, KRW 4.32 billion, and KRW 5.27 billion across the same five quarters, with Q3 2026 showing continued losses that widened year on year.

Losses attributable to controlling shareholders ran for five consecutive quarters from Q3 2025 through Q3 2026, at KRW 5.34 billion, KRW 7.43 billion, KRW 6.58 billion, KRW 9.01 billion, and KRW 5.7 billion.

The four quarters from Q4 2025 through Q3 2026 total KRW 28.7 billion in losses attributable to controlling shareholders.

05

Industry analysis

In MET-targeted oncology, approved drugs already serve patients with MET exon 14 skipping NSCLC, so a new drug's value is judged by efficacy and safety compared with those approved therapies. In a July 2026 note, a Korean securities research team assessed ABN401's antitumor effect as comparable to approved drugs.

The same note said the company plans to complete its Phase 2 trial in Q4 2026 and pursue further technology transfer. In the antibody-drug conjugate market, unmet need after resistance or treatment failure is a main target, and iRAC is presented as an immuno-oncology platform aimed at this area.

Its claim to act in the tumor microenvironment still needs to be demonstrated in clinical data. In Korean biopharma, technology transfer deal size and clinical data are often central to how companies are valued. Sector-wide flows can diverge by company, depending on each company's transfer news and clinical results.

Listed peers in oncology that also pursue technology transfer include LigaChem Biosciences, Hanmi Pharm, and Yuhan, and comparisons of sales and pipelines should be checked against each company's annual report figures.

Abion's competitive position will be shaped by how ABN401's global Phase 2 results are finalized and whether iRAC can show a clinical edge over ADCs.

06

Outlook

The nearest milestone the company has presented is completing the global Phase 2 trial of ABN401 in Q4 2026. In a July 2026 note, a Korean securities research team described this plan together with a stated intention to pursue further technology transfer.

At WCLC 2026 in August 2026, the company said it would meet potential partners interested in ABN401 to share clinical results and development plans and continue discussions on licensing and commercialization.

A company official said the company would expand global partnering talks around ASCO and BIO USA and accelerate technology transfer of key pipeline assets. On the iRAC platform, preclinical and toxicology work on ABN202 is under way, with a target of filing a clinical trial application in the first half of 2027.

Seeking global co-development for candidates such as ABN202 and ABN501 remains an ongoing task. On the results side, Q3 2026 sales of KRW 320 million rose 97.6% year on year, while the operating loss of KRW 5.27 billion widened from a year earlier.

The outlook depends on whether a technology transfer agreement is signed, since current sales are too small to offset losses on their own. The next checkpoint is the 2026 annual report, which will show Q4 2026 and full-year operating margin and operating cash flow. Progress of the listing-related procedure should be checked alongside it.

07

Valuation

PER
—
PBR
1.3×
ROE
-101.8%
EPS
-₩1,593
BPS
₩2,610
Dividend per share
₩0

Net losses attributable to controlling shareholders over the last four quarters mean a price-to-earnings ratio cannot be calculated. The price-to-book ratio sits above 1x, which means the stock trades at a premium to net assets.

That premium reflects expectations for clinical results and technology transfer, and how it is assessed depends on whether those expectations are confirmed by contracts and data.

Total equity at end-2025 was KRW 68.4 billion and total liabilities were KRW 12.2 billion, with the debt-to-equity ratio far below its 2023 level of 347.7%. The dividend yield is close to zero, so dividend-based comparison is limited.

Valuation depends on when earnings recover and how the pipeline is valued, so a single multiple is not enough to reach a conclusion. Comparisons with other listed biopharma companies are limited because pipeline stages and cash burn rates differ.

With no shift from losses to profit yet recorded, the starting point for this stock's valuation is net assets plus pipeline expectations.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

ABN401 Phase 2 data

In the global Phase 2 BICR results presented at ASCO in June 2026, the objective response rate was 55%. Median duration of response was 14.5 months in the overall population and 19.9 months in treatment-naive patients, according to the company.

Grade 3 or higher treatment-related adverse events occurred in 11% of patients, with no Grade 4 events reported. A Korean securities research team in July 2026 assessed the antitumor effect as comparable to approved drugs.

Technology transfer and pipeline expansion

A Korean securities research team reported that the company plans to finish the ABN401 Phase 2 trial in Q4 2026 and pursue further technology transfer. In August 2026, the company said it would meet potential partners during WCLC 2026 to discuss licensing and commercialization.

The iRAC platform has a U.S. patent, and ABN202 is in preclinical work with a target of filing a clinical trial application in the first half of 2027.

Narrower losses and a stronger balance sheet

The operating loss narrowed from KRW 34.1 billion in 2024 to KRW 19.4 billion in 2025. The debt-to-equity ratio fell from 347.7% in 2023 to 126.7% in 2024 and 17.9% in 2025. Q3 2026 sales of KRW 320 million rose 97.6% year on year.

09

Bear factors

Cash outflow and continued losses

Operating cash flow moved from -KRW 19.9 billion in 2022 to -KRW 33 billion in 2025, with a larger outflow each year. Losses ran for four consecutive years from 2022 through 2025 and for five consecutive quarters from Q3 2025 through Q3 2026. Losses attributable to controlling shareholders over the last four quarters total KRW 28.7 billion.

Listing-related disclosures

An IRGO disclosure list shows a trading suspension dated August 14, 2026, tied to a listing-qualification substantive review.

The same list includes a share consolidation decision dated July 2, 2026, results of an extraordinary shareholders meeting dated August 14, 2026, and a share pledge agreement dated July 3, 2026 that accompanies a change in the largest shareholder. The details of each filing and the current trading status should be confirmed in the original DART filings.

Clinical stage and comparison bar

ABN401 is still in a global Phase 2 trial, and its final results and approval timing are not fixed. Approved drugs already exist for MET exon 14 skipping NSCLC, so the company's efficacy and safety claims must hold up against them.

Q3 2026 sales of KRW 320 million are small against an operating loss of KRW 5.27 billion, so current revenue is unlikely to offset losses until technology transfer income is confirmed.

10

Risk factors

Clinical and development

It is not yet confirmed whether ABN401's final Phase 2 results will arrive on the Q4 2026 timeline or whether its safety profile holds in broader patient groups. iRAC candidates such as ABN202 are preclinical, so clinical entry could slip. Development delays would directly affect the timing and terms of technology transfer talks.

Finance and funding

Operating losses and operating cash outflow continue, against total equity of KRW 68.4 billion at end-2025. The funding plan should be checked in the liquidity disclosures of the annual report. The debt-to-equity ratio has fallen, but a fast cash burn could reduce financial flexibility quickly.

Trading and listing

The listing-qualification review, any trading suspension, the share consolidation decision, and the share pledge tied to the largest shareholder are variables for trading conditions and governance. Price volatility and trading liquidity may differ from normal levels. The terms and outcomes of each filing should be checked in the original DART documents.

11

What to watch next

  1. Q4 2026

    Completion of the global ABN401 Phase 2 trial and whether final data are released. Whether results match the company's stated plan will set the starting point for technology transfer talks.

  2. After Q4 2026 (timing not fixed)

    Whether a technology transfer agreement for ABN401 or the iRAC platform is disclosed. The key question is whether partner talks begun at WCLC 2026 lead to signed contracts.

  3. After December 2026 (timing not fixed)

    Outcome of the listing-qualification review and whether the trading suspension is lifted. This directly affects trading conditions and funding options.

  4. First half of 2027

    Target timing for the ABN202 clinical trial application. Preclinical and toxicology results will underpin the clinical entry timeline.

  5. March 31, 2027

    Filing deadline for the 2026 annual report (90 days after fiscal year-end). It is the next periodic report and will show Q4 2026 and full-year operating margin, operating cash flow, and the composition of non-operating items.

12

Overall view

Abion's core assets are the global Phase 2 data for ABN401 (objective response rate of 55%, median duration of response of 19.9 months in treatment-naive patients, and 11% Grade 3 or higher treatment-related adverse events) and the expansion of the iRAC platform.

A Korean securities research team assessed efficacy as comparable to approved drugs, and the company has stated plans to finish Phase 2 in Q4 2026 and pursue further technology transfer.

On the other side, operating cash outflow grew from -KRW 19.9 billion in 2022 to -KRW 33 billion in 2025, and operating losses have run for four years and losses for five straight quarters. Q3 2026 sales rose year on year, but the operating loss widened.

The debt-to-equity ratio fell to 17.9% in 2025, easing balance sheet leverage. A disclosure dated August 14, 2026 lists a trading suspension tied to a listing-qualification substantive review, and the outcome could affect trading conditions and funding. Strengths and weaknesses carry comparable weight here.

The next checkpoints are the final Phase 2 results, whether a technology transfer agreement is signed, the listing review outcome, and full-year figures in the 2026 annual report. This report does not present an investment opinion, rating, or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. thebionews.net
  3. mt.co.kr
  4. newspim.com
  5. mt.co.kr
  6. newspim.com
  7. m.irgo.co.kr
  8. gazet.ai
  9. clinicaltrials.gov
  10. tradingkey.com
  11. comp.fnguide.com
  12. tradingkey.com
  13. tradingkey.com
  14. tradingkey.com
  15. tradingkey.com
  16. kr.investing.com
  17. tradingkey.com
  18. tradingkey.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis